Core Insights - The article highlights the growth and strategic direction of Haofan Bio, a leader in the peptide synthesis reagent sector, emphasizing its commitment to innovation and market stability in the global biopharmaceutical landscape [2][3][4]. Financial Performance - In the first half of 2025, Haofan Bio reported a revenue of 270 million yuan, representing a year-on-year increase of 20.1%, and a net profit attributable to shareholders of 75.88 million yuan, up 15.3% year-on-year [2]. Market Position and Strategy - Haofan Bio has been deeply engaged in the peptide synthesis reagent market for over 20 years, successfully developing first to fourth generation reagents, which positions the company as one of the few global manufacturers covering the entire series [2][4]. - The company aims to build a technological "moat" in the peptide sector, focusing on high-quality products and maintaining its market position through steady innovation [2][4]. R&D and Capacity Expansion - Following its listing on the ChiNext board in 2023, Haofan Bio has accelerated its R&D and production capacity upgrades, including the construction of a new R&D building and the introduction of advanced equipment, increasing its R&D personnel by 30% [3][6]. - The company is also expanding its production bases to alleviate capacity constraints, with plans to establish 3 to 5 workshops at its Huai'an production base by next year [6]. Acquisition Strategy - A key part of Haofan Bio's strategy to address capacity issues includes the planned acquisition of Hangzhou Foster Pharmaceutical for 160 million yuan, which will provide additional production capacity and facilitate the transition of new products from small-scale to larger-scale production [6][7]. Future Outlook - The global peptide drug market is expected to exceed 100 billion USD by 2027, presenting significant growth opportunities for Haofan Bio, although the company acknowledges the challenges posed by rapid changes in pharmaceutical demand [6][7]. - The company emphasizes a cautious approach to future expansions, preferring to focus on solidifying its core product quality and maintaining a stable market position rather than pursuing aggressive acquisitions [6][7].
昊帆生物朱勇：深耕多肽赛道二十载以稳健创新服务全球市场